Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79 (NASDAQ:BVS)November 3, 2026
Share Facebook Twitter LinkedIn Pinterest Email Apellis gets FDA Priority Review for its kidney disease treatment
Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79 (NASDAQ:BVS)November 3, 2026
Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics (NASDAQ:VRTX)November 3, 2026
Apple anticipates December quarter revenue growth of 7%-10% amid supply constraints and higher memory costs (NASDAQ:AAPL)November 3, 2026
